神经酰胺合成酶6通过调控N-RAS/ERK通路影响T细胞同种异体反应与移植物抗宿主病
本研究探讨神经酰胺合成酶6(CerS6)在异基因造血细胞移植后移植物抗宿主病(GVHD)中的作用。遗传或药物靶向CerS6可预防和逆转慢性GVHD;ST1072抑制CerS6可改善急性GVHD同时保留移植物抗白血病效应。机制上CerS6通过影响TCR信号、CD3/PKCθ共定位及N-RAS/ERK通路调控供者CD4 T细胞活化。
要点
- 遗传或药物靶向CerS6可预防和逆转慢性GVHD。
- ST1072抑制CerS6改善急性GVHD且保留GVL效应,不同于FTY720。
- CerS6通过调控TCR信号和N-RAS/ERK通路影响供者CD4 T细胞活化。
核心结论
- 靶向CerS6为控制GVHD和白血病复发提供了依据和手段,可能提高allo-HCT作为血液恶性肿瘤免疫治疗的疗效。
研究设计与样本
- 研究采用遗传或药物靶向CerS6的策略,在异基因造血细胞移植模型中探讨其对急性和慢性GVHD及GVL效应的影响。
主要发现
- 遗传或药物靶向CerS6可预防和逆转慢性GVHD。
- ST1072特异性抑制CerS6显著改善急性GVHD并保留GVL效应,而FTY720减弱急性GVHD但损害GVL活性。
- 阻断CerS6限制供者T细胞迁移至GVHD靶器官,并优先减少供者CD4 T细胞活化。
- CerS6为最佳TCR信号、CD3/PKCθ共定位及后续N-RAS活化和ERK信号所必需,尤其在CD4+ T细胞上。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective immunotherapy for various hematologic malignancies, predominantly through potent graft-versus-leukemia (GVL) effect. However, the mortality after allo-HCT is because of relapse of primary malignancy and followed by graft-vs-host-disease (GVHD) as a major cause of transplant-related mortality. Hence, strategies to limit GVHD while preserving the GVL effect are highly desirable. Ceramide, which serves a central role in sphingolipid metabolism, is generated by ceramide synthases (CerS1-6). In this study, we found that genetic or pharmacologic targeting of CerS6 prevented and reversed chronic GVHD (cGVHD). Furthermore, specific inhibition of CerS6 with ST1072 significantly ameliorated acute GVHD (aGVHD) while preserving the GVL effect, which differed from FTY720 that attenuated aGVHD but impaired GVL activity. At the cellular level, blockade of CerS6 restrained donor T cells from migrating into GVHD target organs and preferentially reduced activation of donor CD4 T cells. At the molecular level, CerS6 was required for optimal TCR signaling, CD3/PKCθ co-localization, and subsequent N-RAS activation and ERK signaling, especially on CD4+ T cells. The current study provides rationale and means for targeting CerS6 to control GVHD and leukemia relapse, which would enhance the efficacy of allo-HCT as an immunotherapy for hematologic malignancies in the clinic.
引用
- Sofi MH, Tian L, Schutt S, et al. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. Leukemia. 2022. PMID: 35513703. doi:10.1038/s41375-022-01581-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。